Skip to main content

Advertisement

Log in

Comparative Brain Exposure to (-)-Carbovir After (-)-Carbovir or (-)-6-Aminocarbovir Intravenous Infusion in Rats

  • Published:
Pharmaceutical Research Aims and scope Submit manuscript

Abstract

Purpose. Evaluate the ability of (-)-6-aminocarbovir ((-)-6AC) to improve the CNS exposure to (-)-carbovir ((-)-CBV).

Methods. Activation of (-)-6AC in vitro was assessed by incubations of rat brain tissue homogenates. The in vivo brain exposure to (-)-CBV was then examined in rats after iv infusions of either (-)-CBV (n = 4) or (-)-6AC (n = 5). The drugs were infused to steady-state via the jugular vein. At the end of the infusion, a bolus of [3H]inulin was injected via the femoral vein in order to obtain an estimate of the brain vascular space.

Results. (-)-6AC was converted to (-)-CBV by incubations of rat brain tissue homogenates. After iv infusion of (-)-CBV, the brain/ blood concentration ratio of (-)-CBV was 0.032 ± 0.009. The brain/ blood concentration ratio of (-)-CBV after iv infusion of (-)-6AC was 0.080 ± 0.020.

Conclusions. (-)-6AC improved the brain delivery of (-)-CBV, although the absolute exposure of the brain tissue to (-)-CBV was still quite low.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Similar content being viewed by others

REFERENCES

  1. R. W. Price, B. Brew, J. Sidtis, M. Rosenblum, A. C. Scheck, and P. Cleary. The brain in AIDS: central nervous system HIV-1 infection and AIDS dementia complex. Science. 239:586–592 (1988).

    Google Scholar 

  2. P. Black. HTLV-III, AIDS and the brain. N. Engl. J. Med. 313(24):1538–1540 (1985).

    Google Scholar 

  3. T. Terasaki and W. M. Pardridge. Restricted transport of 3′-azido-3′-deoxythymidine and dideoxynucleosides through the blood-brain barrier. J. Infect. Dis. 158(3):630–632 (1988).

    Google Scholar 

  4. B. D. Anderson, B. L. Hoesterey, D. C. Baker, and R. E. Galinsky. Uptake kinetics of 2′,3′-dideoxyinosine into brain and cerebrospinal fluid of rats: intravenous infusion studies. J. Pharmacol. Expr. Ther. 253(1):113–118 (1990).

    Google Scholar 

  5. J. M. Gallo, L. N. Clark, and J. T. Rubino. Pump delivery of azidothymidine: potential for constant concentrations and improved brain delivery. J. Cont. Rel. 9:249–253 (1989).

    Google Scholar 

  6. R. E. Galinsky, B. L. Hoesterey, and B. D. Anderson. Brain and cerebrospinal fluid uptake of zidovudine (AZT) in rats after intravenous injection. Life Sci. 47:781–788 (1990).

    Google Scholar 

  7. R. E. Galinsky, K. K. Flaharty, B. L. Hoesterey, and B. D. Anderson. Probenecid enhances central nervous system uptake of 2′,3′-dideoxyinosine by inhibiting cerebrospinal fluid efflux. J. Pharmacol. Expr. Ther. 257(3):972–978 (1991).

    Google Scholar 

  8. A. Namane, C. Gouyette, M.-P. Fillion, G. Fillion, and T. Huynh-Dinh. Improved brain delivery of AZT using a glycosyl phosphotriester prodrug. J. Med. Chem. 35:3039–3044 (1992).

    Google Scholar 

  9. R. L. Lupia, N. Ferencz, J. J. L. Lertora, S. K. Aggarwal, W. J. George, and K. C. Agrawal. Comparative pharmacokinetics of two prodrugs of zidovudine in rabbits: enhanced levels of zidovudine in brain tissue. Antimicrob. Agents Chemother. 37(4): 818–824 (1993).

    Google Scholar 

  10. C. K. Chu, V. S. Bhadti, K. J. Doshi, J. T. Etse, J. M. Gallo, F. D. Boudinot, and R. F. Schinazi. Brain targeting of anti-HIV nucleosides: synthesis and in vitro and in vivo studies of dihydropyridine derivatives of 3′-azido-2′,3′-dideoxyuridine and 3′-azido-3′-deoxy thymidine. J. Med. Chem. 33:2188–2192 (1990).

    Google Scholar 

  11. R. Little, D. Bailey, M. E. Brewster, K. S. Estes, R. M. Clammons, A. Saab, and N. Bodor. Improved delivery through biological membranes. XXXIII. Brain-enhanced delivery of azidothymidine (AZT). J. Biopharm. Sci. 1:1–18 (1990).

    Google Scholar 

  12. M. E. Morgan, S.-C. Chi, K. Murakami, H. Mitsuya, and B. D. Anderson. Central nervous system targeting of 2′,3′-dideoxyinosine via adenosine deaminase-activated 6-halo-dideoxypurine prodrugs. Antimicrob. Agents Chemother. 36(10):2156–2165 (1992).

    Google Scholar 

  13. B. D. Anderson, R. E. Galinsky, D. C. Baker, S.-C. Chi, B. L. Hoesterey, M. E. Morgan, K. Murakami, and H. Mitsuya. Approaches towards the optimization of CNS uptake of anti-AIDS agents. J. Cont. Rel. 19:219–230 (1991).

    Google Scholar 

  14. R. Vince, M. Hua, J. Brownell, S. Daluge, F. Lee, W. M. Shannon, G. C. Lavelle, J. Qualls, O. S. Weislow, R. Kiser, P. G. Canonico, R. H. Schultz, V. L. Narayanan, J. G. Mayo, R. H. Shoemaker, and M. R. Boyd. Potent and selective activity of a new carbocyclic nucleoside analog (carbovir: NSC 614846) against human immunodeficiency virus in vitro. Biochem. Biophy. Res. Commun. 156(2):1046–1053 (1988).

    Google Scholar 

  15. C. L. Zimmerman, R. P. Remmel, S. S. Ibrahim, S. A. Beers, and R. Vince. Pharmacokinetic evaluation of (−)-6-aminocarbovir as a prodrug for (−)-carbovir in rats. Drug Metab. Disp. 20(1):47–51 (1992).

    Google Scholar 

  16. R. Vince and J. Brownell. Resolution of racemic carbovir and selective inhibition of human immunodeficiency virus by the (−)-enantiomer. Biochem. Biophys. Res. Commun. 168:912–916 (1990).

    Google Scholar 

  17. R. Vince and M. Hua. Synthesis and anti-HIV activity of carbocyclic 2′,3′-didehydro-2′,3′-dideoxy-2,6-disubstituted purine nucleosides. J. Med. Chem. 33:17–21 (1990).

    Google Scholar 

  18. Beers, J. Brownell, and R. Vince. Prodrugs of carbovir, a selective inhibitor of HIV: synthesis and enzymatic activation. Proceedings of 199th ACS National Meeting, MEDI#19 (1990).

  19. R. P. Remmel, Y.-H. Yeom, M. Hua, R. Vince, and C. L. Zimmerman. Liquid chromatographic assay of carbovir, a carbocyclic nucleoside active against human immunodeficiency virus. J. Chrom. 489:323–331 (1989).

    Google Scholar 

  20. R. P. Remmel, S.-H. Huang, D. Hoff, and C. L. Zimmerman. Improved fluorometric high-performance liquid chromatographic assay for (−)-carbovir in rat blood and urine. J. Chrom. 534:109–118 (1990).

    Google Scholar 

  21. Q. R. Smith. Quantitation of blood-brain barrier permeability (Chapter 4). In E. A. Neuwelt (ed), Implications of the Blood-Brain Barrier and Its Manipulation, Plenum Medical Book Company, New York and London, 1989.

    Google Scholar 

  22. S.-H. Huang, R. P. Remmel, and C. L. Zimmerman. The bioavailability and nonlinear clearance of (−)-carbovir in the rat. Pharm. Res. 8(6):739–743 (1991).

    Google Scholar 

  23. K. R. Brouwer, R. L. St. Claire, J. Lagarde, J. E. Patanella, J. S. Walsh, and G. T. Miwa. The pharamcokinetics of (−)-carbovir in rats. Evidence for nonlinear elimination. Drug Metab. Disp. 18(6):1078–1083 (1990).

    Google Scholar 

  24. D. H. W. Ho, C. Pincus, C. J. Carter, R. S. Benjamin, E. J. Freireich, and G. P. Bodey, Sr. Distribution and inhibition of adenosine deaminase in tissues of man, rat, and mouse. Cancer Treat. Rep. 64(4–5):629–633 (1980).

    Google Scholar 

Download references

Author information

Authors and Affiliations

Authors

Rights and permissions

Reprints and permissions

About this article

Cite this article

Wen, YD., Remmel, R.P., Pham, P.T. et al. Comparative Brain Exposure to (-)-Carbovir After (-)-Carbovir or (-)-6-Aminocarbovir Intravenous Infusion in Rats. Pharm Res 12, 911–915 (1995). https://doi.org/10.1023/A:1016229624703

Download citation

  • Issue Date:

  • DOI: https://doi.org/10.1023/A:1016229624703

Navigation